Lantheus Medical Imaging

Executive Summary

Lantheus Medical Imaging is a leading radiopharmaceutical company with a 70-year legacy of innovation in diagnostic imaging and targeted radiotherapeutics. The company's 'Find, Fight, Follow' strategy enables early disease detection and precision treatment, primarily in oncology, cardiology, and neurology. With seven commercial products and a valuation of approximately $5 billion, Lantheus holds a strong position in nuclear medicine. Its private structure allows long-term investment in next-generation radiopharmaceuticals, including PSMA-targeted agents for prostate cancer and theranostic approaches for neuroendocrine tumors. Financially robust and commercially proven, the company is poised to capitalize on the expanding radiopharmaceutical market, driven by increased adoption of precision medicine and theranostics. Lantheus's pipeline features novel diagnostic tracers and therapeutic radioconjugates addressing significant unmet needs. Upcoming catalysts include potential FDA approvals for new imaging agents and pivotal clinical trial readouts. The company's focus on prostate cancer and cardiovascular disease positions it for sustained growth. With a strong balance sheet and established revenue streams, Lantheus is well-equipped to navigate regulatory milestones and commercial launches. The convergence of advanced imaging and targeted therapy makes Lantheus a key player in the evolving radiopharmaceutical landscape, offering substantial upside as theranostic paradigms gain traction.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of PSMA-targeted PET imaging agent for prostate cancer80% success
• Q4 2026Positive Phase 3 results for radiopharmaceutical therapeutic in neuroendocrine tumors60% success
• TBDStrategic partnership expansion for radiopharmaceutical manufacturing50% success